For biopharmaceutical companies, gene therapies are an economic challenge. They are expensive to make yet the diseases the treat are rare, so manufacturers tend to charge a lot for them to generate ...

During Q4 2025, callback phishing scams experienced a resurgence, rising from just 3% to a substantial 18% of all phishing incidents. This represents a remarkable 500% spike and underscores a notable ...